1. Home
  2. TNXP vs CWD Comparison

TNXP vs CWD Comparison

Compare TNXP & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$13.73

Market Cap

172.7M

Sector

Health Care

ML Signal

HOLD

Logo CaliberCos Inc.

CWD

CaliberCos Inc.

HOLD

Current Price

$0.99

Market Cap

10.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
CWD
Founded
2007
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
172.7M
10.0M
IPO Year
2008
2022

Fundamental Metrics

Financial Performance
Metric
TNXP
CWD
Price
$13.73
$0.99
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
409.5K
59.8K
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
91.75
N/A
EPS
N/A
N/A
Revenue
$13,107,000.00
$20,097,000.00
Revenue This Year
$558.11
N/A
Revenue Next Year
$38.29
$19.17
P/E Ratio
N/A
N/A
Revenue Growth
29.85
N/A
52 Week Low
$11.60
$0.20
52 Week High
$69.65
$46.21

Technical Indicators

Market Signals
Indicator
TNXP
CWD
Relative Strength Index (RSI) 46.92 37.44
Support Level $13.32 N/A
Resistance Level $20.36 $1.55
Average True Range (ATR) 1.11 0.11
MACD -0.03 -0.02
Stochastic Oscillator 37.75 14.33

Price Performance

Historical Comparison
TNXP
CWD

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About CWD CaliberCos Inc.

CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.

Share on Social Networks: